Global Travel Vaccines Market 2016-2020


#883460

60pages

Technavio

$ 2500

In Stock

About Travel Vaccines
As the world continues to move toward globalization, the international travels will keep increasing. This fuels the demand for travel vaccines as the prevalence of infectious diseases are specifically region prone, unlike that of other indications. As vaccines are largely used as a preventive measure against these known infectious diseases, the travelers are advised to follow the region-specific immunization plan. The market is growing because various government bodies have mandated the immunization of travelers visiting the infectious-prone areas with various types of vaccines. This, in turn, prevents the spread of infection and averts any chances of epidemic outbreaks.

Technavios analysts forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Travel Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
GlaxoSmithKline
Merck
Pfizer
Sanofi

Other prominent vendors
Abbott
AstraZeneca
Bavarian Nordic
Baxter
Beijing Minhai Biotechnology
Bharat Biotech
Bharat Immunologicals and Biologicals
Bio-Med
Seqirus CSL
Crucell
CSL
Dynavax Technologies
Emergent BioSolutions
GlycoVaxyn
GreenSignal Bio Pharma
Hualan Biological Engineering
Imunoloski Zavod
Indian Immunologicals
Janssen Pharmaceuticals
JN International Medical
Kaketsuken
LG Life Sciences
Lupin
Mitsubishi Tanabe Pharma
Novavax
Nuron Biotech
Panacea Biotec
Pfizer
Protein Sciences
Roche
SK Chemicals
Serum Institute of India
Shenzhen Kangtai Biological Products
Sinovac Biotech
Takeda Pharmaceutical
Vacunas Finlay
Valeant Pharmaceuticals
Valneva,
Zydus Cadila

Market driver
Growing demand among travelers
For a full, detailed list, view our report

Market challenge
Requires specific storage and distribution system
For a full, detailed list, view our report

Market trend
Combination vaccines
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.





Table of Contents
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Regulatory scenario of vaccines
PART 06: Market landscape
Market overview
Five forces analysis
PART 07: Market segmentation by disease type
PART 08: Market segmentation by composition
Mono vaccines
Combination vaccines
PART 09: Geographical segmentation
Travel vaccines market in Americas
Travel vaccines market in EMEA
Travel vaccines market in APAC
PART 10: Market drivers
Growing demand among travelers
Additional age group approval
Inclusion in NIP
PART 11: Impact of drivers
PART 12: Market challenges
Requires specific storage and distribution system
High risk and cost involved in vaccine development
Stringent regulatory guidelines
PART 13: Impact of drivers and challenges
PART 14: Market trends
Combination vaccines
Increase in R&D activities
Publicprivate initiatives
PART 15: Vendor landscape
Competitive scenario
Other prominent vendors
PART 16: Key vendor analysis
GlaxoSmithKline
Merck
Pfizer
Sanofi
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Market share of travel vaccines markets in global pharmaceutical market 2015
Exhibit 03: Market share of travel vaccines markets in global pharmaceutical market, 2015
Exhibit 04: Country/region-specific vaccination
Exhibit 05: Key buying criteria for travel vaccines 2015
Exhibit 06: Impact of key customer segments on market 2015
Exhibit 07: Requirements for a BLA submission
Exhibit 08: Stages of vaccine development to obtain license
Exhibit 09: Processes involved in the vaccine development
Exhibit 10: Regulatory testing of licensed vaccines
Exhibit 11: Market snapshot: Global travel vaccines market
Exhibit 12: Worldwide endemicity of HAV infection
Exhibit 13: Endemicity pattern of HBV across various regions
Exhibit 14: Global travel vaccine market snapshot: Developed and emerging markets 2015
Exhibit 15: Overview of vaccine-related acquisitions (2005-2012)
Exhibit 16: Global travel vaccines market 2015-2020 ($ billions)
Exhibit 17: Few of approved travel vaccines
Exhibit 18: Vaccine recommendation for travelers
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation of travel vaccines based on disease type 2015
Exhibit 21: Market share of the different types of travel vaccines based on disease type 2015
Exhibit 22: Overview of global travel vaccines market segmentation based on disease type 2015-2020
Exhibit 23: Global travel vaccines market segmentation by composition
Exhibit 24: Details of approved polysaccharide vaccines
Exhibit 25: Snapshot of global travel vaccines market by geography 2015-2020
Exhibit 26: Global travel vaccines market segmentation by geography 2015-2020 ($ millions)
Exhibit 27: Overview of travel vaccines market in Americas
Exhibit 28: Recommended vaccination for travelers to Mexico
Exhibit 29: Recommended vaccination for travelers to Brazil
Exhibit 30: Travel vaccines market in Americas 2015-2020 ($ billions)
Exhibit 31: Overview of travel vaccines market in EMEA
Exhibit 32: Outbreaks of measles in EMEA during 2011
Exhibit 33: Recommended vaccination for travelers to Italy
Exhibit 34: Recommended vaccinations for travelers to France
Exhibit 35: Recommended vaccinations for some travelers to South Africa
Exhibit 36: Travel vaccines market in EMEA 2015-2020 ($ millions)
Exhibit 37: Overview of travel vaccines market in APAC
Exhibit 38: Recommended vaccination for travelers to India
Exhibit 39: Recommended vaccination for travelers to China
Exhibit 40: Travel vaccines market in APAC 2015-2020 ($ millions)
Exhibit 41: Impact of drivers and challenges on global travel vaccines market
Exhibit 42: Impact of drivers
Exhibit 43: A typical cold chain process
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Impact of trends on global travel vaccines market
Exhibit 46: Competitive structure analysis of global travel vaccines market 2015
Exhibit 47: Key vendors: Geographical presence 2015
Exhibit 48: Competitive assessment of vendors
Exhibit 49: GlaxoSmithKline: Key highlights
Exhibit 50: GlaxoSmithKline: Strength assessment
Exhibit 51: GlaxoSmithKline: Strategy assessment
Exhibit 52: GlaxoSmithKline: Opportunity assessment
Exhibit 53: Merck: Key highlights
Exhibit 54: Merck: Strength assessment
Exhibit 55: Merck: Strategy assessment
Exhibit 56: Merck: Opportunity assessment
Exhibit 57: Pfizer: Key highlights
Exhibit 58: Pfizer: Strength assessment
Exhibit 59: Pfizer: Strategy assessment
Exhibit 60: Pfizer: Opportunity assessment
Exhibit 61: Sanofi: Key highlights
Exhibit 62: Sanofi: Strength assessment
Exhibit 63: Sanofi: Strategy assessment
Exhibit 64: Sanofi: Opportunity assessment